Moderna,Cambridge Massachusetts based company announced early results from its phase one clinical trial Monday morning.According to nbcnews.com,there were 45 participants in total who were given trial drug of phase one .
Each of them received two doses of vaccine about a month apart.Participants were given one of three dosage levels:25 micrograms,100 micrograms and 250 micrograms.
Results of eight participants revealed they develop neutralizing antibodies which are believed to provide protection from virus.The drug is now being tested in larger studies.
Moderna CEO Stephane Bancel said “we couldn’t be happier about this interim data” during the conference call with investors on Monday.
 |
| Add caption |
The result indicate the vaccine has high probability to provide protection from covid-19 in human beings he said.The phase one trial was performed to evaluate the safety of new drugs in small group of people .
Phase two trail is to test whether the drug works or not.
The only side affect the company reports was the redness around the area where the people got shots or vaccine.
Physician who were not involved in the trial expressed the optimism about the results.
No comments:
Post a Comment
if you want leatn more about this blog comment please